What the Fleischner Rules Say About an Incidental Lung Nodule

An incidental lung nodule is a small spot found on a CT scan that was ordered for some other reason, and the 2017 Fleischner Society guidelines exist to answer one practical question about it: how closely, if at all, does it need to be watched. The guidelines sort each nodule using three variables, its size, its composition, and the patient's cancer risk, then translate that combination into a follow-up interval that can range from no imaging at all to a repeat CT within a few months. Written by Heber MacMahon and colleagues and published in Radiology in 2017, they apply to incidental nodules in adults aged 35 and older, and not to nodules found during a formal lung cancer screening program, which runs on a separate system called Lung-RADS.

The three inputs the guideline runs on

Everything in the Fleischner framework flows from three measurements. Get these right and the recommended interval falls out almost mechanically.

Size

Size is the strongest single predictor, and the guideline measures it as the average of the long-axis and short-axis diameters on the same slice, rounded to the nearest millimeter. Two thresholds do most of the work: 6 mm and 8 mm. Below 6 mm, the odds of malignancy sit well under 1 percent, which is the reason the 2017 update raised the size at which routine follow-up even begins. For centers that measure volume rather than diameter, those cutoffs correspond roughly to 100 and 250 cubic millimeters.

Composition

A nodule is either solid or subsolid, and subsolid splits again into pure ground-glass (a hazy patch that does not obscure the underlying lung) and part-solid (a hazy patch with a denser core). The distinction matters because subsolid nodules can represent slow-growing adenocarcinoma-spectrum lesions that need years of surveillance, whereas a tiny solid nodule is usually a scar or an old infection.

Risk

Finally, the patient is stratified as low or high risk. The guideline treats risk as a composite of smoking history, older age, a personal or family history of lung cancer, emphysema or fibrosis on the scan, and morphology such as an upper-lobe location or a spiculated (spiky) edge. A lifelong nonsmoker with a smooth nodule sits at one end; a heavy former smoker with a spiculated upper-lobe lesion sits at the other.

What the intervals actually are

Solid nodules

For a single solid nodule under 6 mm, a low-risk patient generally needs no follow-up at all, while a high-risk patient may be offered an optional CT at 12 months. A solid nodule of 6 to 8 mm calls for a CT at 6 to 12 months, then a further CT at 18 to 24 months in selected cases. Above 8 mm, the guideline moves past simple surveillance and suggests a more definitive workup: an early CT at around 3 months, a PET/CT, or tissue sampling, chosen according to how suspicious the lesion looks. When several solid nodules are present, the follow-up is anchored to the most suspicious one rather than tracked lesion by lesion.

Subsolid nodules

Subsolid nodules are watched longer because the biology is slower. A pure ground-glass nodule under 6 mm needs no routine follow-up. At 6 mm or larger, the guideline recommends a CT at 6 to 12 months to confirm the nodule persists, then continued CT surveillance out to 5 years, since an indolent lesion can take years to declare itself. A part-solid nodule of 6 mm or larger is followed sooner, with a CT at 3 to 6 months to confirm persistence; if it stays put and its solid component remains small, annual imaging continues for about 5 years, and a growing solid core is the finding that prompts escalation.

Why screening follows a different rulebook

The Fleischner guidelines explicitly exclude several groups: anyone under 35, patients with a known primary cancer where the nodule could be a metastasis, and immunosuppressed patients, in whom a nodule is more likely to be infection. They also exclude people being scanned as part of an organized lung cancer screening program. That last exclusion is the one most people run into, so it deserves a clear explanation.

Lung cancer screening in the United States targets a defined high-risk population. The U.S. Preventive Services Task Force recommends annual low-dose CT for adults aged 50 to 80 who have a 20 pack-year smoking history and either still smoke or quit within the past 15 years. Because that population's baseline cancer risk is high and everyone is scanned on the same yearly cadence, screening nodules are managed with the American College of Radiology's Lung-RADS system rather than Fleischner. The current Lung-RADS v2022 sorts findings into structured categories tied to fixed actions: benign-appearing or small nodules return to annual screening, a probably-benign nodule (for example a solid nodule of 6 to 8 mm at baseline) gets a 6-month CT, and a more suspicious category triggers a 3-month CT, PET/CT, or biopsy, with growth defined as a mean-diameter increase greater than 1.5 mm.

The practical contrast is this. Fleischner is a one-time, risk-adjusted decision about an unexpected finding, and it leans on clinical judgment about whether a given patient is low or high risk. Lung-RADS is a repeating annual loop for a pre-selected high-risk group, and it is more algorithmic, assigning a category and a next step with less discretion. Applying one system's thresholds to the other's population is a common source of both over-imaging and missed follow-up.

Keeping the numbers in perspective

A nodule small enough to be measured in millimeters is, in most people, far more likely to be benign than cancerous, and the whole point of graded intervals is to catch the rare exception without subjecting everyone to scans and biopsies they do not need. The intervals are written as ranges precisely so that a clinician can move faster for a worried high-risk patient or slower for a reassuring one. This article is educational and not medical advice; how any specific nodule should be handled depends on the actual images and history, and belongs in a conversation with the physician who ordered the scan.